Literature DB >> 26318108

Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study.

T P Zheng1, Y H Liu2, L X Yang3, S H Qin4, H B Liu5.   

Abstract

OBJECTIVE: Hyperglycemia, insulin resistance, dislipidemia, oxidative stress and inflammation are well-documented risk factors for subclinical atherosclerosis. Dipeptidyl peptidase-4(DPP4) is a newly identified adipokine related to these risk factors. Hence, we aimed to investigate the association between plasma DPP4 activities and subclinical atherosclerosis in type 2 diabetes.
METHODS: A total of 985 newly diagnosed type 2 diabetic subjects were studied. Plasma DPP4 activity, mannose 6-phosphate receptor (M6P-R), oxidative stress parameters, inflammatory markers and common carotid artery Intima-Media Thickness (c-IMT) were measured in all participants.
RESULTS: Participants in the highest quartile of DPP4 activity had higher HbA1c, homeostatic model assessment of insulin resistance(HOMA-IR), triglyceride, low-density lipoprotein cholesterol(LDL-C), oxidized LDL, nitrotyrosine, 8-iso-PGF2a, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), M6P-R, c-IMT compared with participants in the lowest quartile (all P < 0.001). DPP4 activities were associated positively with HbA1c, HOMA-IR, triglyceride, LDL-C, oxidized LDL, nitrotyrosine, 8-iso-PGF2a, IL-6, hs-CRP, M6P-R and c-IMT (all P < 0.05). The ORs for insulin resistance, dislipidemia, oxidative stress and inflammation were higher with increasing DPP4 quartiles (P < 0.001 for trend). In the highest DPP4 quartile, subclinical atherosclerosis risk was significantly higher (OR 4.97; 95% CI 3.03-8.17) than in the lowest quartile. This association remained strong (2.17; 1.21-3.89) after further controlling for HbA1c, HOMA-IR, triglyceride, oxidized LDL, nitrotyrosine, and IL-6.
CONCLUSIONS: This study shows that increased DPP4 activities are positively and independently associated with subclinical atherosclerosis in type 2 diabetes. Our findings suggest of potential role of DPP4 in the pathogenesis of subclinical atherosclerosis and in the prevention and management of this disease.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; DPP4 activity; Dislipidemia; Inflammation; Insulin resistance; Oxidative stress

Mesh:

Substances:

Year:  2015        PMID: 26318108     DOI: 10.1016/j.atherosclerosis.2015.07.042

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

Review 1.  Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

Authors:  John R Ussher; Amanda A Greenwell; My-Anh Nguyen; Erin E Mulvihill
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

2.  Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.

Authors:  Jing Wei Li; Yun Dai Chen; Wei Ren Chen; Jing Jing; Jie Liu; Yong Qiang Yang
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

3.  Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.

Authors:  Enbo Zhu; Lina Hu; Hongxian Wu; Limei Piao; Guangxian Zhao; Aiko Inoue; Weon Kim; Chenglin Yu; Wenhu Xu; Yasuko K Bando; Xiang Li; Yanna Lei; Chang-Ning Hao; Kyosuke Takeshita; Woo-Shik Kim; Kenji Okumura; Toyoaki Murohara; Masafumi Kuzuya; Xian Wu Cheng
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

4.  Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction.

Authors:  Jing-Wei Li; Yun-Dai Chen; Wei-Ren Chen; Qi You; Bo Li; Hao Zhou; Ying Zhang; Tian-Wen Han
Journal:  Cardiovasc Diabetol       Date:  2017-06-06       Impact factor: 9.951

5.  Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways.

Authors:  Xiaoquan Rao; Shi Zhao; Zachary Braunstein; Hong Mao; Michael Razavi; Lihua Duan; Yingying Wei; Amelia C Toomey; Sanjay Rajagopalan; Jixin Zhong
Journal:  EBioMedicine       Date:  2019-02-07       Impact factor: 8.143

6.  Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.

Authors:  Ayano Kubo; Teruo Hidaka; Maiko Nakayama; Yu Sasaki; Miyuki Takagi; Hitoshi Suzuki; Yusuke Suzuki
Journal:  BMC Nephrol       Date:  2020-09-18       Impact factor: 2.388

7.  The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort.

Authors:  Gilberto Vargas-Alarcón; María Del Carmen González-Salazar; Christian Vázquez-Vázquez; Adrián Hernández-Díaz Couder; Fausto Sánchez-Muñoz; Juan Reyes-Barrera; Sergio A Criales-Vera; Marco Sánchez-Guerra; Citlalli Osorio-Yáñez; Rosalinda Posadas-Sánchez
Journal:  Front Genet       Date:  2021-06-11       Impact factor: 4.599

8.  Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.

Authors:  Guang Yang; Yuzi Li; Lan Cui; Haiying Jiang; Xiang Li; Chunzi Jin; Dehao Jin; Guangxian Zhao; Jiyong Jin; Rui Sun; Limei Piao; Wenhu Xu; Chenghu Fang; Yanna Lei; Kuichang Yuan; Chunhua Xuan; Dazi Ding; Xianwu Cheng
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

9.  Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes.

Authors:  Xiang Hu; Xiaojing Ma; Yuqi Luo; Yiting Xu; Qin Xiong; Xiaoping Pan; Yuqian Bao; Weiping Jia
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

10.  Triglyceride-mediated influence of serum angiopoietin-like protein 8 on subclinical atherosclerosis in type 2 diabetic patients: results from the GDMD study in China.

Authors:  Tianpeng Zheng; Bo Ge; Hongbo Liu; Bo Chen; Linyuan Qin; Liuping Xiao; Jianfei Song
Journal:  Cardiovasc Diabetol       Date:  2018-07-15       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.